Skip to main content
. 2020 Mar 17;13(4):100755. doi: 10.1016/j.tranon.2020.100755

Table 2.

Patient characteristics

Median age 49 / (21–63)
Female 3 (21%)
Male 11 (79%)
IDH-1/2 wild-type 12/14 (86%)
Unmethylated MGMT promoter 10/14 (71%)
Response
Complete response (CR) 6 (43%)
Partial response (PR) 6 (43%)
Stable disease (SD) 0 (0%)
Progressive disease (PD) 2 (14%)